OTC : CSPCY
$0.05 (1.24%)
OTC
Lei Cai
Biotechnology
Healthcare
CSPCY
19700
CN
USD
0.02
2.19
1.88
0.60
0.64
$25.29B
3.12
2.43
19.64
1.41
$1.32
$3.78B
14.92%
18.48%
11.47%
8.16%
20.56
-2.54
-2.54
3/5
0 Analysts
%
About CSPC Pharmaceutical Group Limited (OTC:CSPCY) Stock
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various inf ... ections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
2026-07-02 06:16:16
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday.
Frequently Asked Questions
What is the current CSPC Pharmaceutical Group Limited (CSPCY) stock price?
CSPC Pharmaceutical Group Limited(OTC:CSPCY) stock price is $4.09 in the last trading session. During the trading session, CSPCY stock reached the peak price of $5.83 while $3.26 was the lowest point it dropped to. The percentage change in CSPCY stock occurred in the recent session was 1.24% while the dollar amount for the price change in CSPCY stock was $0.05.
CSPCY's industry and sector of operation?
The OTC listed CSPCY is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of CSPCY?
Dongchen Cai
| Executive Chairman
Cuilong Zhang
| Executive Director
Huaiyu Wang
| Executive Director
Weiping Chen
| Executive Director
Xin Cai
| Executive Director
How many employees does CSPCY have?
Number of CSPCY employees currently stands at 19700. CSPCY operates from No.896 Zhongshandong Street, Shijiazhuang, HE 050035, CN.
Link for CSPCY official website?
Official Website of CSPCY is: https://www.cspc.com.hk
How do I contact CSPCY?
CSPCY could be contacted at phone #86 31 1870 37015 and can also be accessed through its website. CSPCY operates from No.896 Zhongshandong Street, Shijiazhuang, HE 050035, CN.
How many shares of CSPCY are traded daily?
The average number of CSPCY shares traded daily for last 3 months was 2.08K.
What is the market cap of CSPCY currently?
The market value of CSPCY currently stands at $11.78B with its latest stock price at $4.09